Arcus Biosciences: A High-Risk Speculation With Multiple Large, Near-Term Catalysts

Arcus Biosciences (NYSE: RCUS ) has undergone a period of mixed developments since last year, and the stock has continued to decline into April 2025. While the company still has sufficient cash and a broad pipeline, the immediate road ahead couldAnalyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in RCUS over the ne ...